博安生物2024年毛利提升32.7%

财中社
Mar 28

3月28日,博安生物(06955)发布截至2024年12月31日止年度的年度业绩公告。业绩显示,公司在报告期间的收入约为7.26亿元,较上年度的6.18亿元增长17.5%。该增长主要源于博优诺®(BA1101)及博优倍®(BA6101)在中国的销售增长以及许可收入的提升。2024年销售成本占总收入的比例由33.9%下降至25.3%。这一变化主要归因于产品产量的增加及生产流程的升级,导致单位制造成本...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10